CD274 and neoplasm: In the future, the key to promoting the development of immunotherapy is to select the best patients according to the molecular classification and immunophenotype of tumor mutation load, MMR status, PD-L1 expression, tumor-infiltrating immune cells, and so on, to truly achieve accurate and personalized treatment.